Shinichi Nakatoh
Overview
Explore the profile of Shinichi Nakatoh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S, et al.
Osteoporos Int
. 2025 Jan;
36(2):363-364.
PMID: 39808194
No abstract available.
2.
Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S, et al.
Osteoporos Int
. 2024 Dec;
36(2):367-368.
PMID: 39680121
No abstract available.
3.
Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S, et al.
Osteoporos Int
. 2024 Dec;
36(2):359-360.
PMID: 39656245
No abstract available.
4.
Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S, et al.
Osteoporos Int
. 2024 Oct;
36(1):81-92.
PMID: 39432088
Purpose: We investigated changes in fracture risk following discontinuation of long-term oral glucocorticoids (GCs) using Japan's nationwide health insurance claims database (NDBJ). Methods: We identified patients aged ≥ 50 years...
5.
Matsumoto S, Hosoi T, Yakabe M, Fujimori K, Tamaki J, Nakatoh S, et al.
Alzheimers Dement
. 2024 Apr;
20(5):3388-3396.
PMID: 38561022
Introduction: There is limited knowledge about early-onset dementia (EOD) on fracture risk. Methods: Individuals ages 50 to 64 were identified from the National Database of Health Insurance Claims and Specific...
6.
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, et al.
Geriatr Gerontol Int
. 2024 Mar;
24(4):390-397.
PMID: 38475987
Aim: This retrospective cohort study assessed the association between the incidence of secondary vertebral fracture managed with a brace (SVF) and pharmacotherapy. Methods: The association between the incidence of SVF...
7.
Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, et al.
Osteoporos Int
. 2024 Jan;
35(5):805-818.
PMID: 38267664
Purpose: Fracture risk assessment is recommended at three months after glucocorticoid (GC) therapy initiation. This study aimed to assess whether GC exposure in the initial 90 days of GC therapy...
8.
Yakabe M, Hosoi T, Matsumoto S, Fujimori K, Tamaki J, Nakatoh S, et al.
Sci Rep
. 2023 Aug;
13(1):12889.
PMID: 37558795
Patients with osteoporosis are prone to fragility fractures. Evidence of the effects of active forms of vitamin D on hip fracture prevention is insufficient. We examined the association between vitamin...
9.
Hosoi T, Yakabe M, Matsumoto S, Fujimori K, Tamaki J, Nakatoh S, et al.
Sci Rep
. 2023 Apr;
13(1):6893.
PMID: 37106031
This retrospective study aimed to evaluate the association between antidementia medication use and incidence of new vertebral, hip, and radial fractures in patients with Alzheimer's dementia (AD). We used the...
10.
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, et al.
J Bone Miner Metab
. 2023 Feb;
41(2):248-257.
PMID: 36853423
Introduction: This study aimed to assess the association between pharmacotherapy and secondary hip fracture incidence. Materials And Methods: The correlation between secondary hip fracture incidence and the presence, type, and...